Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV-116) and other classes of antihypertensive drugs in spontaneously hypertensive rats

Hypertension Research - Clinical and Experimental

Volumn 19, Issue 4, 1996, Pages 247-254

  Wada, Takeo ^a   Sanada, Tsukasa ^a   Ojima, Mami ^a   Kanagawa, Ray ^a   Nishikawa, Kohei ^a   Inada, Yoshiyuki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Angiotensin II antagonist; Calcium antagonist; Candesartan cilexetil; Diuretic; Plasma renin concentration; Spontaneously hypertensive rat; TCV 116; blocker; blocker

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; MANIDIPINE; PRAZOSIN; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIURESIS; DRUG EFFECT; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PULSE RATE; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TACHYCARDIA;

EID: 0030451034     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.19.247     Document Type: Article

References (33)

1. Shibouta Y, Inada Y, Ojima M, et al: Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylic acid CV-11974) and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl]biphenyl-4-yl)-methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
2. Noda M, Shibouta Y, Inada Y, et al: Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993; 46: 311-318.
3. Wada T, Inada Y, Shibouta Y, et al: Antihypertensive action of a nonpeptide angiotensin II (AII) antagonist, TCV-116, in various hypertensive rats. J Hypertens 1992; 10 (Suppl 4): S144.
4. Inada Y, Wada Y, Shibouta Y, et al: Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1-receptor antagonist, (±)-l-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl]biphenyl-4-yl)methyl]-1H-benzimidazole- 7-carboxylate(TCV-116), in various hypertensive rats. J Pharmacol Exp Ther 1994; 268: 1540-1547.
5. Ito K, Shiomi M, Kito G: Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Hypertens Res 1995; 18: 69-75.
6. Wada T, Inada Y, Sanada T, et al: Effect of an angiotensin II antagonist. CV-11974, and its prodrug, TCV-116, on production of aldosterone. Eur J Phar-macol 1994; 253: 27-34.
7. Inada Y, Tanabe M, Kawazoe K, Nishikawa K: Antihypertensivc action of a new angiotensin converting enzyme inhibitor, (R)-3-[(S)-1-carboxy-5-(4-piperidyl) pentyl] amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetic acid (CV-5975), in various hypertensive models. Jpn J Pharmacol 1988; 47: 311-322.
8. Starke K: Regulation of noradrenaline release by presynaptic receptor system. Rev Physiol Biochem Pharmacol 1977; 77: 1-124.
9. Antonaccio MJ, Kerwin L: Pre- and post-junctional inhibition of vascular sympathetic function by captopril in SHR: Implication of vascular angiotensin II in hypertension and antihypertensive actions of captopril. Hypertension 1981; 3 (Suppl 1): 1-54-1-62.
10. Hatton R, Clough DP: Captopril interferes with neurogenic vasoconstriction in the pithed rat by angiotensin-dependent mechanisms. J Cardiovasc Pharmacol 1982; 4: 116-123.
11. Parati G, Mancia G: Calcium antagonists in the treatment of arterial hypertension. Am Heart J 1993; 125 (Suppl 2): 642-648.
12. Elvelin L, Jonsson L: The effect of dihydropyridine calcium antagonists on heart rate: studies of felodipine. Curr Ther Res Clin Exp 1994; 55: 736-746.
13. Nordlander M, Abrahamsson T, Akerblom B, Thalen P: Vascular versus myocardial selectivity of dihydropyridine calcium antagonists as studied in vivo and in vitro. Pharmacol Toxicol 1995; 76: 56-62.
14. Godfraind T: Cardioselectivity of calcium antagonists. Cardiovasc Drugs Ther 1994; 8 (Suppl 2): 353-364.
15. Lindqvist M, Kahan T, Melcher A, Hjemdahl P: Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994; 24: 287-296.
16. Imai K, Higashidate S, Prados PR, Santa T, Adachi-Akahane S, Nagao T: Relation between blood pressure and plasma catecholamine concentration after administration of calcium antagonists to rats. Biol Pharmacol Bull 1994; 17: 907-910.
17. Habermeier-Muth A, Muscholl E: Co-transmitter-mediated facilitation by sympathetic nerve stimulation of evoked acetylcholine release from the rabbit perfused atria preparation. Naunyn Schmiedebergs Arch Pharmacol 1995; 351: 164-172.
18. Inada Y, Shibouta Y, Shimakawa H, Nishikawa K, Kikuchi S: 1,4-dimorpholino-7-phenylpyrido[3,4-d]-pyridazine (DS511) as a new diuretic agent. Arzneim Forsch 1978; 28: 1105.
19. Inada Y, Nishikawa K, Nagaoka A, Kikuchi S: Comparison of the hypotensive and diuretic effects of 1,4-dimorpholino-7-phenylpyrido[3,4-d]pyridazine (DS511) and hydrochlorothiazide in DOCA, renal and spontaneously hypertensive rats. Arzneim Forsch 1977; 27: 1663.
20. Inada Y, Tanabe M, Shibouta Y, Kawazoe K, Nishikawa K, Kikuchi S: Antihypertensive action of a nonsulfhydryl angiotensin converting enzyme inhibitor (CV-3317) in various hypertensive models. Jpn J Pharmacol 1986; 42: 1-8.
21. MacGregor GA, Markandu ND, Banks RA, Bayliss J, Roulston JE, Jones JC: Captopril in essential hypertension: Contrasting effects of adding hydrochlorothiazide or propranolol. Br Med J 1982; 284: 693-696.
22. MacGregor GA, Markandu ND, Smith SJ, Sagnella GA: Captopril: Contrasting effects of adding hydrochlorothiazide, propranolol or nifedipine. J Cardiovasc Pharmacol 1985; 7: S82-S87.
23. DeForrest JM, Waldron TL, Powell JR, Floyd DM, Sundeen JE: SQ27,786 and SQ28,853: Two angiotensin converting enzyme inhibitors with potent diuretic activity. J Cardiovasc Pharmacol 1987; 9: 154-159.
24. Wong PC, Price WA, Chiu AT, et al: Nonpeptide angiotensin II receptor antagonists. IX. Anti-hypertensive activity in rats of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 726-732.
25. Keeton TK, Cambell WB: The pharmacologie alteration of renin release. Pharmacol Rev 1981; 31: 81-227.
26. Belz GG, Essig J, Kleinbloesem CH, Hoogkamer JFW, Wiegand UW, Wellstein A: Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agoinst dose-effect curves and baroreceptor reflex. Br J Clin Pharmacol 1988; 26: 547-556.
27. Beiz GG, Breithaupt K, Erb K, Kleinbloesem CH, Wolf GK: Influence of the angiotensin converting enzyme inhibitor cilazapril, the β-blocker propranolol and their combination on haemodynamics in hyper-tension. J Hypertens 1989; 7: 817-824.
28. Erb KA, Breithaupt EK, Belz GG: Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. Drugs 1991; 41 (Suppl 1): 11-17.
29. Kleinbloesem CH, van Brummelen P, Francis RJ, Wiegand UW: Clinical pharmacology of cilazapril. Drugs 1991; 41 (Suppl 1): 3-10.
30. CIBIS Investigators and Committees: A randomized trial of β-blockade in heart failure. The cardiac insufficiency bisoprolol study. Circulation 1994; 90: 1765-1773.
31. Davis JO, Freeman RH: Mechanisms regulating renin release. Physiol Rev 1976; 56: 1-56.
32. 8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; ii: 1045-1048.
33. Mooser V, Nussberger J, Juillerat L, et al: Reactive hyperreniemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 35: 276-282.